Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Detalles Bibliográficos
Autores principales: Pokorna, Petra, Lakka Klement, Giannoula, Vasikova, Alzbeta, Kanderova, Veronika, Jezova, Marta, Noskova, Kristyna, Mudry, Peter, Kyr, Michal, Merta, Tomas, Bajciova, Viera, Krenova, Zdenka, Palova, Hana, Valik, Dalibor, Zdrazilova Dubska, Lenka, Slaby, Ondrej, Sterba, Jaroslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384955/
https://www.ncbi.nlm.nih.gov/pubmed/35700412
http://dx.doi.org/10.1200/PO.21.00525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384955/
https://www.ncbi.nlm.nih.gov/pubmed/35700412
http://dx.doi.org/10.1200/PO.21.00525

Ejemplares similares